Enjoy complimentary customisation on priority with our Enterprise License!
The Global antiemetics drugs market size is estimated to grow by USD 1.72 billion, at a CAGR of 6.48% between 2023 and 2028. The increase in the prevalence of nausea and vomiting stands as a pivotal driver molding the market landscape. These distressing symptoms afflict millions worldwide, stemming from various illnesses and treatments. With cancer diagnoses escalating and advancements in therapy, a burgeoning number of patients endure chemotherapy-induced nausea and vomiting (CINV). The quest for potent antiemetic drugs to mitigate CINV and enhance patients' treatment journey intensifies. Additionally, motion sickness plagues many travelers, whether for work or leisure, contributing to nausea and vomiting occurrences. Consequently, patients necessitate antiemetic medications to effectively manage these symptoms, fostering positive market growth prospects. A comprehensive analysis delves into drivers, trends, and obstacles, shedding light on the market dynamics.
To learn more about this report, Request Free Sample
The market share growth by the 5-Hydroxytryptamine 3 segment will be significant during the forecast period. Chemotherapy drugs are effective at removing cancer cells, but they can also be harmful to normal cell types, such as those in the gut and vomiting centers of the brain. The goal of antiemetic therapy in CINV is to provide effective control of nausea and vomiting, allowing patients to tolerate and complete their chemotherapy treatments without interruptions or dose reductions.
Get a glance at the market contribution of various segments View a PDF Sample
The 5-Hydroxytryptamine 3 segment was valued at USD 1.36 billion in 2018. The management of CINV typically involves a combination of antiemetic medications targeting multiple pathways involved in the development of nausea and vomiting. Thus, growing cases of cancer globally will drive the demand for chemotherapy, which, in turn, will boost the growth of the market in focus on the chemotherapy segment during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America held the largest share of the market in 2022. North America comprises countries such as the US, Canada, and Mexico, and it represents a key region for the development, manufacturing, and consumption of antiemetic drugs, which is driving the growth of the regional market. Several of the leading pharmaceuticals are based in North America, developing and manufacturing antiepileptic medicines. These companies invest in research and development to introduce innovative drugs with improved efficacy and safety profiles.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market players, including:
Boehringer Ingelheim International GmbH - The company offers an antiemetic drug, namely OFEV.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companiesas pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companiesas dominant, leading, strong, tentative, and weak.
The antiemetic drug market encompasses a wide range of medications used to prevent and alleviate symptoms of vomiting and nausea. These medications are essential for managing various conditions, including rotavirus gastroenteritis treatments and postoperative surgery. The market for antiemetic drugs is significant, with major retail pharmacies and online pharmacies such as CVS Pharmacy, Walgreens Boots Alliance, and Rite Aid, among others, stocking a variety of antiemetic options. Generic substitutes play a crucial role in the antiemetic drug market, providing affordable alternatives to branded medications. For instance, Barhemsys, a recently FDA-approved antiemetic, is available in both branded and generic forms. The Association of Anesthetists recognizes the importance of antiemetic drugs in managing anesthesia-related nausea and vomiting. Overall, the antiemetic drug market continues to evolve, with ongoing research and development efforts aimed at improving existing treatments and discovering new ones. There are multiple factors influencing market growth.
The increasing healthcare expenditure is a key driver shaping the market. Global health expenditure is driven by factors like population growth, aging demographics, technological progress, and the prevalence of chronic diseases. As healthcare systems invest more in providing comprehensive medical care, the demand also experiences a parallel increase. The growth of the worldwide market for antiepileptic drugs is underpinned by increasing access to healthcare and coverage. Additionally, the rise of e-commerce has facilitated easier access to medications and health products, while the widespread use of smartphones has enhanced patient engagement and adherence through health apps and telemedicine services. Together, these advancements contribute to the expanding market for antiepileptic drugs and broader healthcare services.
However, as more individuals gain access to healthcare services, the demand for various medications increases. Improved access to healthcare allows patients to seek timely and appropriate treatment for conditions that may cause nausea and vomiting, leading to the rising need for antiemetics. In addition, driving health expenditure and, consequently, demand for antiemetic medicinal products is also played out by government initiatives and insurance programs that promote better access to healthcare. As healthcare becomes more accessible and affordable, patients can access essential medications, such as antiemetics, without financial barriers, which will contribute to the growth of the market in focus during the forecast period.
The rising demand in emerging economies is a primary trend in the market. A significant trend in the global pharmaceutical market is the rising demand for antiepileptic drugs in developing countries. Emerging economies are experiencing an increase in the prevalence of diseases and conditions that cause nausea and vomiting. The rising incidence of cancer, gastrointestinal disorders, infectious diseases, and the use of chemotherapy regimens contribute to the higher demand for effective antiemetic drugs. In order to improve the outcomes and quality of life for patients, an increased emphasis has been placed on addressing symptoms such as nausea and vomiting when developing healthcare systems in these countries.
Additionally, there is a growing awareness of healthcare and increased accessibility to medical services in emerging economies. Patients are becoming more informed about their healthcare needs and seeking better management of their symptoms, including nausea and vomiting. The growth of healthcare infrastructure in emerging economies plays a significant role in driving demand for antiemetics. The availability and use of those medicinal products are enhanced by the presence of well-equipped health facilities and trained healthcare professionals. Thus, the growing demand in emerging economies is one of the emerging trends that is expected to drive the market growth and trends.
High entry barriers for new players are major challenges impeding the growth of the market. Due to the presence of larger market players, it is far from easy for SMEs to come up with novel products that can penetrate the market. In addition, a significant role in the market scenario is played by switching costs for buyers as well as the trust of public companies. Also, these bigger companies have large distribution channels and operate in collaboration with all the major leading hospitals and health centers, which poses a big challenge for newer companies to penetrate the market.
Therefore, customers show resistance toward the adoption of newer products. The major undertakings also offer a wide range of products that are typically impossible to compete with the new and developing players. With various products to choose from, buyers tend to incline more on these bigger companies that have higher brand values. Smaller companies also have limited resources and funding, with no major collaborators. With fewer products in the line, if approvals get delayed every time, it comes as a major drawback since product launch delays will have an impact on vendors' revenues. Thus, high entry barriers for new players are expected to pose a negative impact on the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Market Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
Serotonin receptor antagonists, such as Sancuso manufactured by Cumberland Pharmaceuticals, are essential medications used to prevent nausea and vomiting (emesis) in children undergoing chemotherapies. The effectiveness and safety of Sancuso were recently studied and published in the Official Journal of the American Academy of Pediatrics. The Centers for Disease Control and Prevention (CDC) focuses on the importance of managing chemotherapy-induced emesis to ensure optimal treatment outcomes and improve patients' quality of life. Sandoz, a leading pharmaceutical company, also offers similar serotonin receptor antagonists to help alleviate symptoms of chemotherapy-induced ailments, including vertigo, in adult patients. These drugs or medications play a crucial role in mitigating the adverse effects of chemotherapies, enhancing patients' overall well-being.
However, in the healthcare sector, the National Library of Medicine is a valuable resource for researching various medical topics, including frontiers in neuroscience and the use of dopamine receptor antagonist drugs. One such drug is Fosaprepitant, which is used to prevent nausea and vomiting caused by chemotherapy. General anesthetics, another important topic, can also lead to side effects like dizziness and emotional stress. Cancer statistics highlight the need for effective treatments and medications, such as antihistamines and anticholinergics, which can alleviate symptoms and improve patient comfort. Gravisetron, a serotonin antagonist, is another medication used to prevent nausea and vomiting. Surgeries, a common application of anesthetics, can also lead to side effects, making it crucial to understand the mechanisms of these drugs and their potential interactions.
Further, the market is witnessing significant growth driven by various factors, such as the widespread use of opioid analgesics and radiation therapy. Patients undergoing treatment for cancer, metabolic disorders, or post-operative surgery often experience nausea and vomiting as side effects, necessitating the use of antiemetic drugs. Moreover, conditions like food poisoning, dehydration, and esophageal tears can also lead to severe nausea and vomiting, further boosting the demand for antiemetic medications. The market is supported by ongoing investments in research and development to improve drug efficacy and dosage formulations. However, patent expiration and regulatory restraints pose challenges to market growth despite estimations of increased usage in hospital pharmacies and surgical procedures. Furthermore, the Technavio market growth analysis report has segmented the market into Application, Drug, and Geography.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
184 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.48% |
|
Market growth 2024-2028 |
USD 1.72 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.74 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 41% |
|
Key countries |
US, China, Germany, UK, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Algen Healthcare Ltd., Boehringer Ingelheim International GmbH, Bristol Laboratories Ltd., Cadila Pharmaceuticals Ltd., Cipla Inc., Eagle Pharmaceuticals Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., RedHill Biopharma Ltd., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, Market growth and Forecasting, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.